Ipamorelin

Overview

Ipamorelin is a five-amino-acid synthetic peptide that tells your pituitary gland to release growth hormone — and it does it more selectively than almost anything else in its class. That selectivity is the whole point. Older growth hormone secretagogues like GHRP-6 and GHRP-2 work, but they also drag cortisol and prolactin up with them. Ipamorelin doesn't. You get the GH pulse without the hormonal noise.

It was developed in the late 1990s by Novo Nordisk and studied in human volunteers as early as 1999.[1] The pharmacokinetic data from those early trials confirmed what animal studies suggested: ipamorelin produces a sharp, dose-dependent GH spike with a relatively clean side effect profile.[1] That profile is why it became one of the more widely used peptides in hormone optimization clinics over the past decade.

It's not FDA approved. It's used in the US primarily as a research compound, and in some clinical settings through compounding pharmacies. If you're considering it, that regulatory reality matters — and it's covered in detail below.

Mechanism of Action

Ghrelin receptor (GHS-R1a) agonism → pulsatile GH release

Ipamorelin is a ghrelin mimetic — it binds to the same receptor that the hunger hormone ghrelin activates, called GHS-R1a (growth hormone secretagogue receptor type 1a). That receptor sits on somatotroph cells in the anterior pituitary gland. When ipamorelin binds to it, those cells release a pulse of growth hormone into circulation.

What happens next is the downstream cascade most people care about. The GH pulse travels to the liver, where it stimulates production of IGF-1 (insulin-like growth factor 1). IGF-1 is the primary mediator of GH's anabolic effects: it promotes muscle protein synthesis, supports bone density, influences fat metabolism, and plays a role in tissue repair. In rat models, ipamorelin produced dose-dependent increases in longitudinal bone growth rate and body weight at doses of 18–450 mcg/day subcutaneously over 15 days.[2] A separate study found that ipamorelin increased bone mineral content in adult female rats, comparable to effects seen with GHRP-6 and exogenous GH.[3]

The ghrelin receptor is also expressed in the hypothalamus, which is why ghrelin itself makes you hungry. Ipamorelin has some appetite-stimulating effect through this pathway, but it's milder than GHRP-6 — the compound's selectivity for the pituitary over the hypothalamus is part of what keeps the side effect profile cleaner.

Importantly, ipamorelin works within the body's existing feedback system. It amplifies a natural GH pulse rather than bypassing the axis entirely the way exogenous recombinant GH does. Somatostatin — the hormone that tells the pituitary to stop releasing GH — still functions normally. That built-in brake is one reason ipamorelin is considered lower-risk than exogenous GH from a regulatory and physiological standpoint, though this comparison hasn't been formally tested in long-term human trials.

What the Evidence Shows

The honest answer is that the human evidence base for ipamorelin is thin. What exists is promising but limited.

The foundational human study is the 1999 pharmacokinetic-pharmacodynamic modeling study by Raun et al., published in Pharmaceutical Research.[1] It examined ipamorelin's PK and PD in healthy human volunteers, confirming dose-dependent GH release and establishing the compound's selectivity profile — specifically, that it did not meaningfully elevate cortisol or prolactin at the doses tested. This study is the bedrock of what we know about ipamorelin in humans, and it's worth being clear: it was a PK/PD study, not an efficacy trial. It told us the compound works mechanistically in humans. It didn't tell us whether it improves muscle mass, reduces body fat, or extends healthspan in a controlled clinical setting.

The animal data is more extensive. Ipamorelin produced dose-dependent longitudinal bone growth in adult female rats over 15 days of subcutaneous administration.[2] A subsequent study found that 28 days of ipamorelin at 0.5 mg/kg/day increased bone mineral content in young adult female rats, with effects comparable to GHRP-6 and exogenous GH.[3] These findings support the mechanistic plausibility of ipamorelin for bone and body composition applications, but rat studies don't translate directly to human outcomes.

In the context of hypogonadism management, a 2020 review in Translational Andrology and Urology discussed GH secretagogues — including ipamorelin — as a potential adjunctive therapy for body composition changes in hypogonadal males, noting that current clinical data remains limited.[4]

A 2026 review in The American Journal of Sports Medicine included ipamorelin among therapeutic peptides being marketed to patients for orthopaedic and sports medicine applications, highlighting the gap between patient demand and the available evidence base.[5]

Side Effects
Ipamorelin's selectivity profile means its side effect burden is generally lighter than older GHRPs, but that doesn't mean side-effect-free. Here's what the data and clinical experience actually suggest:

If you develop significant joint pain, numbness in the hands, or notice meaningful changes in fasting glucose, those are signals to pause and check in with your prescribing provider — not wait for the next scheduled appointment.